spacer
home > white papers > Sourcing Commercial Drugs for Clinical Trials: US vs. EU Understanding the Differences - Myoderm
WHITE PAPERS
logo_Myoderm.JPG

Myoderm

phone +1 610-233-3300
email sales@myoderm.com
web http://www.myoderm.com
email 48 East Main Street, Norristown, PA 19401 USA

Sourcing Commercial Drugs for Clinical Trials: US vs. EU Understanding the Differences

Sourcing commercial drugs for clinical trials is a dynamic process. There are many factors to consider: single source or regional sourcing, strategy, price, supply availability, lead times, and documentation are just a few. In the past, there were fewer clinical trials that required commercial drug sourcing, so demand was not as high. Today, the demand for commercial drugs in clinical trials has greatly increased and, as a result, inventory is tighter, orders are monitored more closely by manufacturers, and lead times have increased. This report highlights the key differences in sourcing from the US and EU.
Sourcing Commercial Drugs for Clinical Trials: US vs. EU Understanding the Differences
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Extremely fast chemical search in vast chemical space

Read through a poster by ChemAxon aiming to find novel analogues of known drugs among the 977 million unique entries of the GDB-13 database. The result got queried against the SureChEMBL's patent database as well.
More info >>


White Papers

The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology

European Society for Medical Oncology (ESMO)

  The number of cancer patients in Europe is rising and significant advances in basic and applied cancer research are making the provision of optimal care more challenging. The concept of cancer as a systemic, highly heterogeneous and complex disease has increased the awareness that quality cancer care should be provided by a multidisciplinary team (MDT) of highly qualified healthcare professionals. Cancer patients also have the right to benefit from medical progress by receiving optimal treatment from adequately trained and highly skilled medical professionals. Built on the highest standards of professional training and continuing medical education, medical oncology is recognised as an independent medical specialty in many European countries.
More info >>


Industry Events

DIA 2018 Global Annual Meeting

24-28 June 2018, Boston, MA

The DIA 2018 Global Annual Meeting brings together thousands of innovators from around the globe. Designed to drive insights into action by connecting key policy discussions to real-world knowledge that you need to do your job every day, your attendance will accelerate your growth and your organization's performance in the development ecosystem.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement